- Conditions
- Post Operative Surgical Site Infection
- Interventions
- Standard of care, Vancomycin and Tobramycin
- Drug
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 31
- States / cities
- Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 67
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
- Interventions
- CEM-102, IV or Oral standard of care antibiotics, Rifampin
- Drug
- Lead sponsor
- Arrevus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Syphilis
- Interventions
- Group B, Linezolid 10d, Group A, Penicillin
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Jackson, Mississippi • Greensboro, North Carolina + 1 more
- Conditions
- Healthy Subjects
- Interventions
- TR-701, linezolid, placebo
- Drug
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Interventions
- TR-701 FA, Linezolid
- Drug
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more
- Conditions
- Skin Diseases, Bacterial
- Interventions
- Intravenous iclaprim, Intravenous linezolid
- Drug
- Lead sponsor
- Arpida AG
- Industry
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Naperville, Illinois • Casper, Wyoming
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Methicillin Resistant Staphylococcus Aureus (MRSA)
- Interventions
- linezolid (Zyvox), vancomycin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 71 more
- Conditions
- Complicated Skin and Skin Structure Infection
- Interventions
- intravenous iclaprim or intravenous linezolid
- Drug
- Lead sponsor
- Arpida AG
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 5
- States / cities
- National City, California • Boise, Idaho • Indianapolis, Indiana + 2 more
- Conditions
- Bacterial Infections, Skin Structures and Soft Tissue Infections
- Interventions
- Omadacycline, Linezolid
- Drug
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more
- Conditions
- Methicillin-resistant Staphylococcal Aureus Pneumonia
- Interventions
- etest susceptability testing
- Other
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- Not listed
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Pneumonia, Methicillin-Resistant Staphylococcus Aureus
- Interventions
- Polymerase Chain Reaction (PCR)
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream, Infection, Bacterial, Streptococcal Toxic Shock Syndrome
- Interventions
- Linezolid, Clindamycin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
- Interventions
- Radezolid, Linezolid
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 19
- States / cities
- Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
- Interventions
- linezolid, vancomycin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,077 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 76
- States / cities
- Montgomery, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
- Conditions
- Bacterial Infection
- Interventions
- ceftaroline, linezolid, Aztreonam
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 13
- States / cities
- Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
- Conditions
- Tuberculosis
- Interventions
- Gatifloxacin, Isoniazid, Levofloxacin, Linezolid, Moxifloxacin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
- Interventions
- Vancomycin, Ceftaroline, Daptomycin, Linezolid
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Bacterial Pneumonia
- Interventions
- IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 8
- States / cities
- San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Bacterial Infections
- Interventions
- Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Chula Vista, California • La Mesa, California • Oceanside, California + 2 more
- Conditions
- Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
- Interventions
- Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Tuberculosis
- Interventions
- PNU-100480, Placebo, Linezolid
- Drug
- Lead sponsor
- Sequella, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Interventions
- IV Dalbavancin, Vancomycin/Linezolid
- Drug
- Lead sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 739 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 30
- States / cities
- Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more